Tscan Therapeutics is trading at $0.22, down 5.80%, amid biotech weakness, though the sector decline does not establish the cause of its move.
- Supplied sector data show XBI down 2.01% during the session; the decline may have contributed.
- No new company-specific announcement was listed on Tscan Therapeutics’ official press-release page; its latest listed release was dated September 2, 2026.
- No reliable volume or activity data were provided.